Key result
The integration of an ultra-sensitive pulse wave sensor with a three-dimensional management model significantly reduced median NT-proBNP levels (142 vs 155 pg/mL, p<0.001) and improved LVEF (0.45 vs 0.43, p=0.030) at 6 months compared to the management model alone in patients with chronic heart failure.
Why the study?
The study was conducted to investigate whether combining an ultra-sensitive pulse wave sensor with a three-dimensional hospital-community-family management model improves clinical outcomes in heart failure patients.
Does an ultra-sensitive pulse wave sensor combined with a three-dimensional hospital-community-family model improve NT-proBNP and LVEF in patients with chronic heart failure?
RCT (n=172)
Open-label
1:1
Yes
Does an ultra-sensitive pulse wave sensor combined with a three-dimensional hospital-community-family model improve NT-proBNP and LVEF in patients with chronic heart failure?
The integration of an ultra-sensitive pulse wave sensor with a three-dimensional hospital-community-family model significantly improves cardiac function, exercise tolerance, and quality of life in patients with chronic heart failure.
May support sensor-enhanced HF care pathways; leaves open need for confirmatory trials before practice change.
目的:本研究目的旨在探讨超灵敏脉波传感器联合医院社区家庭三维模式在心衰患者管理中的应用,以改善患者的临床结局。方法:本研究为多中心、前瞻性、随机、对照研究,选取2020年1月1日~2023年12月30日于青岛大学附属医院及市南区社区卫生服务中心就诊的心力衰竭(CHF)患者,按照入选及排除标准共纳入172例CHF患者进入本研究,并随机分为三维模式观察组、传感器联合三维模式观察组。根据课题设计给予不同干预方式,平均随访时间为6个月,观察两组患者干预随访后NT-proBNP、左室射血分数(LVEF)值指标的变化,以及六分钟步行测试(6MWT)、生活质量表(MLHFQ)评分、再住院率的差异。结果:干预随访后,观察组与联合观察组的LVEF值显著升高,NT-proBNP水平显著降低,且联合观察组的效果最为显著,差异有统计学意义(P 0.05),但联合观察组和观察组均显示出下降趋势,且联合观察组下降幅度最大。结论:通过超灵敏脉波传感器联合三维模式在心衰患者管理中的应用能够改善患者预后,降低再住院率,提高患者的生活质量,展现出良好的临床应用前景。Objective: The purpose of this study was to investigate the application of an ultra-sensitive pulse wave sensor combined with three-dimensional hospital-community-family model in the management of heart failure (HF) patients to improve clinical outcomes. Methods: This multicenter, prospective, randomized, controlled trial included 172 patients with chronic heart failure (CHF) admitted to the Affiliated Hospital of Qingdao University and Shinan District Community Health Service Center between January 1, 2020, and December 30, 2023, who met predefined inclusion and exclusion criteria. Participants were randomized into two groups: a three-dimensional model observation group, and a sensor combined with three-dimensional model observation group. Interventions were administered according to the study protocol, with a mean follow-up period of 6 months. Outcomes assessed included changes in NT-proBNP levels, left ventricular ejection fraction (LVEF), 6-minute walk test (6MWT) distance, Minnesota Living with Heart Failure Questionnaire (MLHFQ) scores, and rehospitalization rates. Results: After the intervention and follow-up, both the observation group and the combined observation group showed significantly increased LVEF values and significantly reduced NT-proBNP levels, with the most pronounced effects observed in the combined observation group (P 0.05), both the combined observation group and the observation group exhibited a downward trend, with the largest reduction seen in the combined observation group. Conclusion: The integration of an ultra-sensitive pulse wave sensor with a three-dimensional hospital-community-family model in HF management improves prognosis, reduces rehospitalization trends, enhances quality of life, and exhibits significant clinical potential for optimizing patient care.
No takes yet. Share an insight, caveat, or question.
辉 房 (2025) conducted an RCT in Chronic Heart Failure (n=172). Ultra-sensitive pulse wave sensor combined with three-dimensional hospital-community-family management model vs. Three-dimensional hospital-community-family management model was evaluated on NT-proBNP at 6 months (p=<0.001). The integration of an ultra-sensitive pulse wave sensor with a three-dimensional management model significantly reduced median NT-proBNP levels (142 vs 155 pg/mL, p<0.001) and improved LVEF (0.45 vs 0.43, p=0.030) at 6 months compared to the management model alone in patients with chronic heart failure.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: